MarketPulse

COVID-19 vaccine

5 articles
BenzingaBenzinga··Vandana Singh

Moderna Shares Slide Despite Revenue Beat, Weighed by $2.22B Legal Settlement

Moderna beats revenue estimates with $389M vs. $227.97M consensus but shares fall 2.05% due to $2.22 per share litigation settlement charge.
PFEMRNABNTX2026 guidancebiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Nuvaxovid Outperforms Moderna mRNA Vaccine in Tolerability Study

Sanofi's Nuvaxovid shows 50% fewer severe side effects than Moderna's mRNA vaccine in clinical trial, with patients twice as likely to choose it again.
SNYMRNAclinical trialCOVID-19 vaccine
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi

Sanofi's Nuvaxovid Shows Superior Safety Profile Against Moderna's mRNA Vaccine

Sanofi's protein-based COVID-19 vaccine demonstrated significantly lower side effects than Moderna's mNEXSPIKE in head-to-head trial of 1,000 adults.
SNYMRNAclinical trialCOVID-19 vaccine
BenzingaBenzinga··Vandana Singh

Moderna Settles $950M Patent Dispute, Clears Path for Profitability Push

Moderna settles $950M patent dispute with Arbutus and Genevant, clearing legal uncertainty. Stock surges 8.85% as company targets 2028 breakeven with $4.5-5B cash by 2026.
MRNABNTXROIVABUSbalance sheet strengthmRNA technology
BenzingaBenzinga··Vandana Singh

BioNTech Sues Moderna Over Patent Rights to Next-Gen COVID Vaccine

BioNTech sues Moderna for patent infringement over next-gen COVID vaccine technology, claiming mNEXSPIKE violates its spike protein patents. Seeking damages for unlicensed use.
PFEMRNABNTXintellectual propertymRNA technology